AAM
AMRI

AMI Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

AMI Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-735,876
Closed -$16M – 79
2017
Q2 		$16M Buy
735,876
+30,383
+4% +$551K 1.14% 34
2017
Q1 		$9.9M Sell
705,493
-97,236
-12% -$1.59M 0.75% 51
2016
Q4 		$15.1M Sell
802,729
-50,275
-6% -$855K 1.11% 42
2016
Q3 		$14.1M Sell
853,004
-23,439
-3% -$347K 0.97% 48
2016
Q2 		$11.8M Buy
876,443
+313,225
+56% +$4.57M 0.82% 51
2016
Q1 		$8.61M Buy
563,218
+69,745
+14% +$1.09M 0.59% 55
2015
Q4 		$9.79M Buy
493,473
+113,887
+30% +$2.16M 0.68% 55
2015
Q3 		$6.61M Buy
+379,586
New +$7.73M 0.51% 55

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

AMI Asset Management's AMRI Position: Q3 2017 in Review

AMI Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 735,876 shares — an estimated $16M sold.

AMI Asset Management first reported a position in AMRI in Q3 2015 and held it in 8 quarters. The position peaked at $16M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • AMI Asset Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • AMI Asset Management sold 735,876 Albany Molecular Research Inc shares in Q3 2017, an estimated $16M.
  • AMI Asset Management first reported a position in Albany Molecular Research Inc in Q3 2015 and held it in 8 quarters.
  • AMI Asset Management's Albany Molecular Research Inc position peaked at $16M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on AMI Asset Management's 13F filing for Q3 2017, filed 10 Oct 2017.